Masthead

Fresh Options Raise Optimism About Leukemia Care

| Comments (0)

New drugs and new combinations under development bring a targeted approach to improving care for chronic lymphocytic leukemia (CLL) and for overcoming drug-resistant chronic myeloid leukemia (CML).

"It's an optimistic time for us," says William Wierda, M. D., Ph.D., associate professor in the department of Leukemia, during a video interview about CLL with Andrew Schorr of Patient Power

CLL Therapy Increasing Survival from Patient Power® on Vimeo.

In separate interviews, Wierda and Michael Keating, M.D., discuss new drugs, clinical trials and how M. D. Anderson doctors work with referring physicians to manage patient care.


An Expert's Perspective on the Latest CLL News from Patient Power® on Vimeo.

A class of drugs called tyrosine kinase inhibitors has increased five-year survival for CML patients from 50 percent to 90 percent in recent years.  Yet for some patients, their CML does not respond or becomes resistant over the course of treatment.

In second video interview with Schorr, Jorge Cortes, M.D., professor in the department of Leukemia, discusses drugs in clinical trials that show promise against resistant CML.

Fighting Drug Resistance in CML from Patient Power® on Vimeo.


Both interviews occurred at the 51st Annual Meeting of the American Society of Hematology in New Orleans Dec. 5-8.

Other M. D. Anderson interviews on Patient Power can be viewed at  www.mdanderson.org/patientpower

Leave a comment

Search

Connect on social media

Sign In

Archives